A major observational study comparing DOACS in older patients with atrial fibrillation has shown they all have significant benefits over warfarin in terms of reducing thromboembolic stroke, intracranial haemorrhage and all-cause mortality. Twice-daily DOACS dabigatran and apixaban were associated with a more favourable benefit-to-harm ration than the once-daily rivaroxaban, according to the retrospective new-user cohort ...
DOACS not all equal, FDA study suggests
By Michael Woodhead
16 Apr 2019